Riskpilot← Back to searchSign inGet full accessNestInvest 2 ApS
APSActiveCVR 39807114Hejrevej 39, 1.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20182 employees
Revenue 2024
DKK 1,2M
+32% vs 2023
EBITDA margin
100.0%
+32% vs 2023
Equity ratio
75.4%
Financial strength
Net profit 2024
DKK 947K
+40% vs 2023
| Revenue | DKK 1,2M | +32% |
| EBITDA | DKK 1,2M | +32% |
| Net profit | DKK 947K | +40% |
| Total assets | DKK 2,1M | +17% |
| Equity | DKK 1,5M | +29% |
| Employees | 2 | — |
Legal name
NestInvest 2 ApS
CVR number
39807114
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23. august 2018
Share capital
DKK 50.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af 1 direktør
Company purpose
Selskabets formål er at drive handels-, rådgivnings- og konsulentvirksomhed inden for den farmaceutiske og medikotekniske industri
Address
Hejrevej 39, 1.
Phone
+4570204107
Email
mrh@macurepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -6 | 33 | 2.237 | 3.708 | 928 | 1.225 |
| Staff expenses | -0 | -0 | -2.059 | -3.152 | -3 | -0 |
| EBITDA | -6 | 33 | 178 | 555 | 925 | 1.225 |
| Depreciation & amort. | -0 | -10 | -30 | -30 | -30 | -30 |
| EBIT | -6 | 23 | 148 | 525 | 895 | 1.195 |
| Net financials | -0 | -6 | -27 | -46 | -28 | 19 |
| Profit before tax | -7 | 17 | 121 | 479 | 867 | 1.214 |
| Tax | -2 | 4 | 27 | 105 | 191 | 267 |
| Net profit | -5 | 13 | 95 | 374 | 676 | 947 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 50 | 426 | 2.446 | 1.656 | 1.762 | 2.055 |
| Equity | 45 | 58 | 152 | 526 | 1.202 | 1.549 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 361 | 2.283 | 1.117 | 544 | 487 |
| Total debt | 5 | 361 | 2.283 | 1.117 | 544 | 487 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20192024
Equity ratio
75.4%
This company
38.2%
Market median
+97% vs market
20192024
Return on equity
61.1%
This company
18.4%
Market median
+232% vs market
20192024
Net profit margin
77.3%
This company
8.1%
Market median
+854% vs market
20192024
Asset turnover
0.60×
This company
1.12×
Market median
-46% vs market
20192024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-23 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LM Management | Management | 2018 | — | — |
MR Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nest Egg ApS | Company | 100.0% | 100.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
POMALA HOLDING ApS
NestInvest 2 ApS Board members of NestInvest 2 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Mark Poulsen | Management | 0 companies |
| Mads Renlef Henningsen | Chief Executive Officer | 0 companies |